Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trefoil Selects AGC Biologics as Lead Manufacturer of TTHX1114","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptvac Signs Agreement with AGC Biologics to Develop & Produce COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"N\/A","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"N\/A"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Inks Manufacturing Deal with Faron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"N\/A","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"N\/A"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Selects AGC Biologics to Manufacture Matrix-M\u2122 Adjuvant for Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Saiba AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saiba AG and AGC Biologics Enter COVID-19 Vaccine Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Molecular Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin\u00ae Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"MolMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC to Complete the Acquisition of MolMed on July 31, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Expands Partnership with Novavax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics and Horizon Therapeutics plc Expand Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Expands Partnership with Rocket Pharmaceuticals","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oculis Selects AGC Biologics\u2019 Heidelberg Facility to Manufacture OCS-02","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Inks Supply Deal for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene\u2019s New Cell Therapy Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by AGC Biologics

    Menu

    AGC Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma

              Details:

              AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

              Lead Product(s): Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

              Therapeutic Area: Oncology Product Name: Hu14.18K322A

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Recipient: Essential Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

              Details:

              Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.

              Lead Product(s): MDG1015,PD1-41BB

              Therapeutic Area: Oncology Product Name: MDG1015

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Medigene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project

              Details:

              Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: The Jikei University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy

              Details:

              Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.

              Lead Product(s): Teplizumab-mzwv

              Therapeutic Area: Endocrinology Product Name: Tzield

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Provention Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate

              Details:

              Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

              Lead Product(s): VLP Peanut

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Vaccine

              Recipient: Allergy Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

              Details:

              Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

              Lead Product(s): VLP-Based Peanut Allergy Vaccine

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Allergy Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics Inks Supply Deal for COVID-19 Vaccine

              Details:

              AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine (BNT162b2) manufacturing process.

              Lead Product(s): BNT162b2

              Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2

              Highest Development Status: Phase IV Product Type: Vaccine

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

              Details:

              OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.

              Lead Product(s): OCS-02

              Therapeutic Area: Ophthalmology Product Name: OCS-02

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oculis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AGC Biologics Expands Partnership with Rocket Pharmaceuticals

              Details:

              Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV, which includes RP-L102 genetically modified with a lentiviral vector.

              Lead Product(s): RP-L102

              Therapeutic Area: Rare Diseases and Disorders Product Name: RP-L102

              Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Rocket Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AGC Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

              Details:

              AGC Biologics will manufacture GMP material for the next stage of clinical trial. ER-004 is an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.

              Lead Product(s): ER-004

              Therapeutic Area: Genetic Disease Product Name: EDI200

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY